PMHS
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $1M | $34,376 |
| 2025 Q4 | -0.33 | $632,056 | $190,021 |
| 2025 Q3 | -0.02 | $6,163 | -$352,659 |
| 2025 Q2 | -0.02 | $5,470 | -$187,780 |
| 2025 Q1 | -0.02 | $4,542 | -$45,577 |
| 2024 Q4 | 0.05 | $48,975 | -$314,995 |
| 2024 Q3 | -0.10 | $9,849 | -$715,564 |
| 2024 Q2 | -0.00 | $0 | -$80,121 |